Afatinib in Subjects With Kidney Dysfunction

Inclusion criteria: * Despite renal impairment (group 1 and 2) healthy males or females according to the investigators assessment, as based on the following criteria: a complete medical history including a physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests. * Glomerular filtration rate (GFR), estimated according to: \-- MDRD (Modification of Diet in Renal Disease)-formula: * eGFR (estimated Glomerular Filtration Rate) \[ml/min/1.73m²\]= 175 x Serum Creatinine-1.154 x age-0.203 (if male) * eGFR\[ml/min/1.73m²\]= 175 x Serum Creatinine-1.154 x age-0.203 x 0.742 (if female) * 30 to 59 mL/min for moderate renal impairment group 1 * 15 to 29 mL/min for severe renal impairment group 2 * = 90 mL/min for healthy volunteers group 3 * Age =18 and =79 years Exclusion criteria: * Any finding of the medical examination (including Blood Pressure (BP), Pulse Rate (PR) and Electrocardiogram (ECG)) deviating from normal and of clinical relevance, e.g. repeated measurement of systolic blood pressure \< 90 mmHg (millimeter of mercury) or \> 140 mmHg, diastolic blood pressure \< 50 mmHg or \> 90 mmHg, repeated measurement of pulse rate \< 45 bpm (beats per minute) or \> 90 bpm. * Any evidence of a clinically relevant concomitant disease. * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, dermatological or hormonal disorders. * Relevant gastrointestinal tract surgery (except appendectomy). * Diseases of the central nervous system (such as epilepsy, seizures) or psychiatric disorders or neurological disorders. * History of photosensitivity or recurrent rash. * Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders.